HP
ICCC icon

HealthInvest Partners’s ImmuCell ICCC Stock Holding History

HealthInvest Partners’s Portfolio ICCC Stock Details ICCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-182,133
Closed -$1.33M – 14
2017
Q2 		$1.33M Buy
182,133
+13,810
+8% +$82K 1.66% 11
2017
Q1 		$931K Hold
168,323
– – 1.43% 10
2016
Q4 		$1M Hold
168,323
– – 0.92% 15
2016
Q3 		$1.3M Hold
168,323
– – 0.97% 13
2016
Q2 		$1.16M Hold
168,323
– – 0.53% 18
2016
Q1 		$1.15M Buy
168,323
+43,031
+34% +$287K 0.54% 18
2015
Q4 		$945K Buy
125,292
+16,542
+15% +$117K 0.44% 14
2015
Q3 		$647K Hold
108,750
– – 0.38% 14
2015
Q2 		$854K Buy
108,750
+2,200
+2% +$15.1K 0.44% 13
2015
Q1 		$670K Hold
106,550
– – 0.46% 14
2014
Q4 		$518K Buy
106,550
+1,200
+1% +$5.72K 0.43% 16
2014
Q3 		$524K Buy
105,350
+26,873
+34% +$126K 0.38% 16
2014
Q2 		$345K Sell
78,477
-2,469
-3% -$10.4K 0.19% 19
2014
Q1 		$389K Buy
80,946
+11,338
+16% +$49.3K 0.28% 17
2013
Q4 		$297K Buy
+69,608
New +$301K 0.3% 17

Other funds holding ICCC

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SRC
Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EFS
Essex Financial Services Essex, Connecticut $1.78B AUM 23.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return

HealthInvest Partners's ICCC Position: Q3 2017 in Review

HealthInvest Partners sold out of ImmuCell (ICCC) in Q3 2017, closing a stake of 182,133 shares — an estimated $1.33M sold.

HealthInvest Partners first reported a position in ICCC in Q4 2013 and held it in 15 quarters. The position peaked at $1.33M in Q2 2017. 15 funds tracked by Wall St. Rank hold ICCC as of Q3 2017.

  • HealthInvest Partners reported no remaining ImmuCell position as of Q3 2017 after selling out during the quarter.
  • HealthInvest Partners sold 182,133 ImmuCell shares in Q3 2017, an estimated $1.33M.
  • HealthInvest Partners first reported a position in ImmuCell in Q4 2013 and held it in 15 quarters.
  • HealthInvest Partners's ImmuCell position peaked at $1.33M in Q2 2017.
  • 15 funds tracked by Wall St. Rank held ImmuCell as of Q3 2017.

Based on HealthInvest Partners's 13F filing for Q3 2017, filed 13 Nov 2017.